Answers are grounded in this paper and cite their sources.
A first-in-human trial demonstrated that a vaccine targeting the histone mutation H3K27M can induce an immune response, in a mutation-specific manner, in patients with diffuse midline glioma. In a recent study by Boschert et al., the same group now dissects the functional immune response triggered after effective vaccination of one of the patients, who has been in remission for over 3 years. The H3K27M peptide vaccine, named H3-vac, induces a CD4
No takes yet. Share an insight, caveat, or question.
Vincent et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: